Skip to content

CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please ensure that you fully understand the risks involved.

Trader thoughts - The long and short of it

After all the excitement yesterday, confirming that all financial markets do actually have a pulse and that they can actually fall, we should see more reserved conditions today.

Market Data
Source: Bloomberg

Whether we’re seeing the ‘calm before the storm’ was the question asked yesterday. Remember this is a market that is still so full of complacency, and clearly long equities and short US Treasuries. The prospect of increased volatility is real, although that proposition still sounds too good to be true, at least for the traders out there. Calmer conditions and leads have been offered for Asia though, and with perhaps the exception of Japan, we should see a modest upside to the various Asian indices, but there won’t be any real conviction behind the buying.

This was thematic yesterday, where there were so few buyers and the markets fell under their own weight. Has the overnight session provided any clarity and renewed optimism to wade in? I don’t believe so.

So once again financial strategists become political pundits, as we try and assess the probability of House Speaker Paul Ryan’s healthcare plan being passed through the House. We know the Republicans hold 237 of the 430 seats in the House (or 55.1%) and effectively need 216 votes to get the required majority. However, Alyssa Farah, spokesperson for the Freedom Caucus (the collective who want Obamacare to be completely torn apart and reworked), has suggested that they have 25 hard ‘no’ votes, and Trump and Ryan cannot afford any more than 21. This suggests Trump/Ryan would be four votes shy of the required tally to get the bill over the line, given every Democrat will vote against this bill.

Clearly, the Freedom Caucus want their time in the sun and want to be heard. This could be the second big loss for President Trump after his immigration order was rejected. This vote then during Asian trade tomorrow (no set time as of yet - http://www.house.gov/) will be seen as a proxy for the strength of the mandate that Trump has had to govern. There is no tax reform without the Ryan healthcare plan voted through. However, the likelihood is that it will be reworked and voted on again in the future. This is a key event risk for tomorrow, and as I mention, likely to keep the buyers in Asia at bay.

If we look at other markets to view semantics, we can see small buying in US fixed income, with the US five-year Treasury falling a couple of basis points to 1.93%, and the five-year ‘real’ yields still just in negative territory. The USD index is largely unchanged, but is still holding under the 100 level. Even though we have seen some buying in the likes of the ZAR and other emerging market currencies, the AUD has certainly not fared as well, although is now eyeing a move back into the trading session highs of $0.7691. Small buying has also been seen in high yield credit, with the  Shares High Yield corporate exchange traded fund (HYG ETF) gaining 0.3%.

It all suggests calmer conditions from the prior session, but as I mention, it’s all about tomorrow. It would be interesting if we actually saw the Bill being passed, followed by a strong (February) durables goods data (consensus 1.3%). New York Fed president Bill Dudley speaks at 1.00am AEDT on Saturday morning and if he talks up the prospect of a June Fed hike, given financial conditions are still so accommodative, then things will get very interesting. Obviously a lot of hypotheticals, but do we start saying the reflation trade is back on if this scenario plays out? These are fickle markets.

Turning to the Asian open, it’s interesting that SPI futures have pushed up 17 points, largely as a function that S&P 500 futures are 8 points, or 0.4% higher from the ASX 200 close. So a number of traders who had positioned for another night of fairly heavy selling have likely closed out of SPI futures shorts.

As far as sector leads go in the S&P 500, the buying really centred on tech. This won’t really help the ASX 200 too greatly. US financials and materials are largely unchanged, but BHP’s ADR (American Depository Receipt) is up 0.8%. CBA’s ADR is 0.5%. Commodity leads are mixed, with spot iron ore falling 3% to $84.99 and the days of calling $100 spot prices seem a distant memory. Iron ore and steel futures (traded on the Dalian exchange) has pulled back 1% and 0.2% respectively. Gold is modestly high, as is US crude, which is actually around 20c higher from the ASX 200 close, despite a 4.95 million barrel increase in the weekly (official) inventory data. The offset being a sizeable draw in gasoline inventories of 2.81 million.

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IG Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.

Find articles by writer